Skip to main content
SpringerLink
Log in

Long-term effectiveness of enzyme replacement therapy in Fabry disease: results from the NCS-LSD cohort study

  • Original Article
  • Published:
Journal of Inherited Metabolic Disease

Abstract

Objectives

To determine the effectiveness of enzyme replacement therapy (ERT) for adults and children with Fabry disease.

Design

Cohort study including prospective and retrospective clinical data. Age- and gender-adjusted treatment effects were estimated using generalised linear mixed models. Treated patients contributed data before and during treatment and untreated patients contributed natural history data.

Participants

Consenting adults (N = 289) and children (N = 22) with a confirmed diagnosis of Fabry disease attending a specialist Lysosomal Storage Disorder treatment centre in England. At recruitment 211 adults and seven children were on ERT (range of treatment duration, 0 to 9.7 and 0 to 4.2 years respectively).

Outcome measures

Clinical outcomes chosen to reflect disease progression included left ventricular mass index (LVMI); proteinuria; estimated glomerular filtration rate (eGFR); pain; hearing and transient ischaemic attacks (TIA)/stroke.

Results

We found evidence of a statistically significant association between time on ERT and a small linear decrease in LVMI (p = 0.01); a reduction in the risk of proteinuria after adjusting for angiotensin-converting enzyme inhibitors and angiotensin receptor blockers (p < 0.001) and a small increase in eGFR in men and women without pre-treatment proteinuria (p = 0.01 and p < 0.001 respectively). The same analyses in children provided no statistically significant results. No associations between time on ERT and pain, risk of needing a hearing aid, or risk of stroke or TIAs, were found.

Conclusions

These data provide some further evidence on the long-term effectiveness of ERT in adults with Fabry disease, but evidence of effectiveness could not be demonstrated in children.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  • Alegra T, Vairo F, de Souza MV, Krug BC, Schwartz IV (2012) Enzyme replacement therapy for Fabry disease: a systematic review and meta-analysis. Genet Mol Biol 35(4 (suppl)):947–954

  • Banikazemi M, Bultas J, Waldek S et al (2007) Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 146(2):77–86

    Article  PubMed  Google Scholar 

  • Beck M, Ricci R, Widmer U et al (2004) Fabry disease: overall effects of agalsidase alfa treatment. Eur J Clin Invest 34(12):838–844

    Article  PubMed  CAS  Google Scholar 

  • Connock M, Juarez-Garcia A, Frew E, et al (2006) A systematic review of the clinical effectiveness and cost-effectiveness of enzyme replacement therapies for Fabry's disease and mucopolysaccharidosis type 1. Health Technol Assess 10(20): iii-iv, ix-113

  • Desnick RJ, Wasserstein MP (2001) Fabry disease: clinical features and recent advances in enzyme replacement therapy. Adv Nephrol Necker Hosp 31:317–339

    PubMed  CAS  Google Scholar 

  • Devereux RB, Alonso DR, Lutas EM et al (1986) Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 57(6):450–458

    Article  PubMed  CAS  Google Scholar 

  • El Dib RP, Nascimento P, Pastores GM (2013) Enzyme replacement therapy for Anderson-Fabry disease. Cochrane Database Syst Rev 2, CD006663

    PubMed  Google Scholar 

  • Eng CM, Banikazemi M, Gordon RE et al (2001) A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet 68(3):711–722

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Germain DP, Waldek S, Banikazemi M et al (2007) Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol 18(5):1547–1557

    Article  PubMed  CAS  Google Scholar 

  • Hajioff D, Enever Y, Quiney R, Zuckerman J, Mackermot K, Mehta A (2003) Hearing loss in Fabry disease: the effect of agalsidase alfa replacement therapy. J Inherit Metab Dis 26(8):787–794

    Article  PubMed  CAS  Google Scholar 

  • Henley W, Anderson LJ, Wyatt KM, Nikolaou V, Anderson R, Logan S (2014) The NCS-LSD cohort study: a description of the methods and analyses used to assess the long-term effectiveness of enzyme replacement therapy and substrate reduction therapy in patients with lysosomal storage disorders. JIMD Rep (in press)

  • Hoffmann B, Reinhardt D, Koletzko B (2004) Effect of enzyme-replacement therapy on gastrointestinal symptoms in Fabry disease. Eur J Gastroenterol Hepatol 16(10):1067–1069

    Article  PubMed  Google Scholar 

  • Hoffmann B, Beck M, Sunder-Plassmann G, Borsini W, Ricci R, Mehta A (2007) Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy–a retrospective analysis from the Fabry Outcome Survey. Clin J Pain 23(6):535–542

    Article  PubMed  Google Scholar 

  • Hughes DA, Elliott PM, Shah J et al (2008) Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart 94(2):153–158

    Article  PubMed  CAS  Google Scholar 

  • Lang RM, Bierig M, Devereux RB et al (2006) Recommendations for chamber quantification. Eur J Echocardiogr 7(2):79–108

    Article  PubMed  Google Scholar 

  • Levey AS, Coresh J, Greene T et al (2006) Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145(4):247–254

    Article  PubMed  CAS  Google Scholar 

  • Mehta A, Ginsberg L (2005) Natural history of the cerebrovascular complications of Fabry disease. Acta Paediatrica 94(s447):24–27

    Article  PubMed  CAS  Google Scholar 

  • Mehta A, Ricci R, Widmer U et al (2004) Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 34(3):236–242

    Article  PubMed  CAS  Google Scholar 

  • Mehta A, Beck M, Elliott P et al (2009) Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data. Lancet 374(9706):1986–1996

    Article  PubMed  CAS  Google Scholar 

  • Moore DF, Altarescu G, Herscovitch P, Schiffmann R (2002) Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease. BMC Neurol 2:4

    Article  PubMed  PubMed Central  Google Scholar 

  • Motwani M, Banypersad S, Woolfson P, Waldek S (2012) Enzyme replacement therapy improves cardiac features and severity of Fabry disease. Mol Genet Metab 107(1–2):197–202

    Article  PubMed  CAS  Google Scholar 

  • Rombach SM, Smid BE, Bouwman MG, Linthorst GE, Dijkgraaf MG, Hollak CE (2013) Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain. Orphanet J Rare Dis 8:47

    Article  PubMed  PubMed Central  Google Scholar 

  • Rombach SM, Smid BE, Linthorst GE, Dijkgraaf MG, Hollak CE (2014) Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis : Effectiveness of ERT in different disease stages. J Inherit Metab Dis (in press)

  • Schafer E, Baron K, Widmer U et al (2005) Thirty-four novel mutations of the GLA gene in 121 patients with Fabry disease. Hum Mutat 25(4):412

    Article  PubMed  Google Scholar 

  • Schiffmann R, Kopp JB, Austin HA 3rd et al (2001) Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285(21):2743–2749

    Article  PubMed  CAS  Google Scholar 

  • Schiffmann R, Warnock DG, Banikazemi M et al (2009) Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant 24(7):2102–2111

    Article  PubMed  PubMed Central  Google Scholar 

  • Schiffmann R, Martin RA, Reimschisel T et al (2010) Four-year prospective clinical trial of agalsidase alfa in children with Fabry disease. J Pediatr 156(5):832–837, 837 e831

    Article  PubMed  CAS  Google Scholar 

  • Schwartz GJ, Munoz A, Schneider MF et al (2009) New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20(3):629–637

    Article  PubMed  PubMed Central  Google Scholar 

  • Sims K, Politei J, Banikazemi M, Lee P (2009) Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry. Stroke 40(3):788–794

    Article  PubMed  Google Scholar 

  • Stevens LA, Coresh J, Greene T, Levey AS (2006) Assessing kidney function–measured and estimated glomerular filtration rate. N Engl J Med 354(23):2473–2483

    Article  PubMed  CAS  Google Scholar 

  • Tondel C, Bostad L, Larsen KK et al (2013) Agalsidase benefits renal histology in young patients with Fabry disease. J Am Soc Nephrol 24(1):137–148

    Article  PubMed  CAS  Google Scholar 

  • Vedder AC, Linthorst GE, Houge G et al (2007) Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg. PLoS One 2(7):e598

    Article  PubMed  PubMed Central  Google Scholar 

  • Wanner C, Oliveira JP, Ortiz A et al (2010) Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry. Clin J Am Soc Nephrol 5(12):2220–2228

    Article  PubMed  PubMed Central  Google Scholar 

  • Warnock DG, Ortiz A, Mauer M et al (2012) Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation. Nephrol Dial Transplant 27(3):1042–1049

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Weidemann F, Niemann M, Breunig F et al (2009) Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation 119(4):524–529

    Article  PubMed  CAS  Google Scholar 

  • Weidemann F, Niemann M, Stork S et al (2013) Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications. J Intern Med 274(4):331–341

    Article  PubMed  CAS  Google Scholar 

  • Wilcox WR, Banikazemi M, Guffon N et al (2004) Long-term safety and efficacy of enzyme replacement therapy for Fabry Disease. Am J Hum Genet 75:65–74

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Wilcox WR, Oliveira JP, Hopkin RJ et al (2008) Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab 93(2):112–128

    Article  PubMed  CAS  Google Scholar 

  • Wraith JE, Tylki-Szymanska A, Guffon N et al (2008) Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease. J Pediatr 152(4):563–570, 570 e561

    Article  PubMed  CAS  Google Scholar 

  • Wyatt K, Henley W, Anderson L et al (2012) The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders. Health Technol Assess 16(39):1–543

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

We thank study site personnel Marie Meehan, Andrea Hill, Debbie Hugh, Sarah West, Sandhya Maddukuri, Kate Blackler, Hannah Russon, Navneeta Reddy, Jennifer Hutchinson, Nike Aina and Noura Hamdi for their hard work in the recruitment of patients to this study, and in managing the patients’ data at each of the seven sites. We thank the late Ed Wraith, Robin Lachmann, Atul Mehta, Ashok Vellodi, Patrick Deegan, Tim Cox, Chris Hendriksz, Philip Lee, Uma Ramaswami, Simon Jones and Tanya Collin-Histed for their contribution to the design and conduct of the study. Thanks to Rob Anderson for his contribution to the design of the study and data collection forms, to Sheena Oxer and Louise Klinger for their contribution to the set-up and coordination of the study, and to Laura Cocking for her help in the design and the management of the databases throughout the study.

We are grateful to all members of the LSD patient support groups and the Trial Steering Committee. Finally, special thanks to the patients and their families who allowed us to collect information from their hospital records and gave their time to complete the questionnaires. We thank them for their invaluable contribution.

Compliance with ethics guidelines

ᅟ

Conflicts of interest

Lindsey Anderson, Katrina Wyatt, William Henley, Vasilis Nikolaou and Stuart Logan declare that they have no conflicts of interest.

Stephen Waldek is a member of the Fabry Registry Board and the Fabry Expert Group and has received funding for research, and honoraria for lectures and consultancy on research studies from Shire HGT and Genzyme. He has also received research grants from Biomarin, Synageva and Amicus.

Derralynn Hughes has received funding for research and travel to meetings, honoraria for lectures and consultancy projects or advisory boards from Shire HGT, Genzyme, Amicus, Actelion, and Biomarin. Consultancy and advisory board work is administered via UCL business and used in part to fund research.

Gregory M. Pastores has received funding for research and travel to meetings, honoraria for lectures and consultancy projects or advisory boards from Shire HGT, Genzyme, Amicus, Actelion, and Biomarin.

Informed consent

All procedures were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 (5). Informed consent was obtained from all patients before being included in the study.

Author information

Authors and Affiliations

  1. Institute of Health Research, University of Exeter Medical School, Veysey Building, Salmon Pool Lane, Exeter, Devon, UK, EX2 4SG

    L. J. Anderson, K. M. Wyatt, W. Henley, V. Nikolaou & S. Logan

  2. Independent Medical Consultant, Retired Metabolic Physician, Formerly of Salford Royal NHS Foundation Trust, Salford, UK

    S. Waldek

  3. Department of Haematology, Royal Free Campus, University College, London, UK

    D. A. Hughes

  4. Department of Medicine/National Centre for Inherited Metabolic Disorders, Mater Misericordiae University Hospital, Eccles Street, Dublin 7, Ireland

    G. M. Pastores

Authors
  1. L. J. Anderson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. M. Wyatt
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W. Henley
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. V. Nikolaou
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. Waldek
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D. A. Hughes
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. G. M. Pastores
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S. Logan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K. M. Wyatt.

Electronic supplementary material

Below is the link to the electronic supplementary material.

ESM 1

(DOCX 36 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Anderson, L.J., Wyatt, K.M., Henley, W. et al. Long-term effectiveness of enzyme replacement therapy in Fabry disease: results from the NCS-LSD cohort study. J Inherit Metab Dis 37, 969–978 (2014). https://doi.org/10.1007/s10545-014-9717-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10545-014-9717-4

Keywords

Search

Navigation